Hem
Shkreli, Wu-tang Clan

USA:s mest hatade vd köpte hemligt Wu Tang Clan-album

Turing Pharmaceuticals vd Martin Shkreli har kallats för USA:s mest hatade vd. Orsaken är att hans bolag köpte rättigheterna till ett läkemedel som används av cancer- och aidspatienter – och sedan höjde priset med 5 000 procent. Nu har han lyckats buda hem det enda exemplaret av hip hop-gruppen Wu-Tang Clans album ”Once Upon a Time in Shaolin”, rapporterar Bloomberg. Varken Wu-Tang Clan eller Shkreli vill berätta hur högt priset blev. Enligt Bloomberg ska det ha rört sig om motsvarande 17 miljoner kronor.

bakgrund
 
Shkreli har sagt att han ska sänka priset på preparatet – något som ännu inte skett
Wikipedia (en)
Martin Shkreli (born April 1, 1983) is an American entrepreneur and financial and pharmaceutical executive. Shkreli is a co-founder of the hedge fund MSMB Capital Management, was co-founder and former CEO of the biotechnology firm Retrophin LLC, and founded and leads, as of December 2015, Turing Pharmaceuticals AG. In September 2015, Shkreli was criticized when Turing Pharmaceuticals obtained the manufacturing license for Daraprim, and raised its price by 5,455 percent (from $13.50 to $750 per tablet).
bakgrund
 
Wu-Tang Clan bildades 1992
Wikipedia (en)
The Wu-Tang Clan /ˈwuːtæŋklæn/ is an American hip hop group from New York City, originally composed of East Coast rappers RZA, GZA, Method Man, Raekwon, Ghostface Killah, Inspectah Deck, U-God, Masta Killa and the late Ol' Dirty Bastard. The group was formed in and is associated with the New York City borough of Staten Island. The Wu-Tang Clan has introduced and launched the careers of a number of affiliated artists and groups, often collectively known as the Wu-Tang Killa Bees, and in 2008, About.com ranked them the No. 1 greatest hip hop group of all time" Kris Ex of Rolling Stone called Wu-Tang Clan "the best rap group ever". In 2004, NME hailed them as one of the most influential groups of the last ten years.
Omni är politiskt obundna och oberoende. Vi strävar efter att ge fler perspektiv på nyheterna. Har du frågor eller synpunkter kring vår rapportering? Kontakta redaktionen